Overview
EBS market data
Price History
EBS price chart
Valuation & Profitability
- P/E (TTM)
- 4.44 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.93 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.25 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.36 – $14.06 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $233.3M · P/B 1.24 · P/S 0.34.
Company News
HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $10Benzinga · Aug 10, 2026, 10:13 AM
U.S. CDC Says As Of August 6, 2,465 Confirmed Measles Cases Were Reported In U.S. In 2026; There Have Been 38 New Measles Outbreaks Reported In 2026, And 94% Of Confirmed Cases Are Outbreak-AssociatedBenzinga · Aug 7, 2026, 3:06 PM
Emergent BioSolutions shares are trading lower after the company lowered its FY2026 sales guidance.Benzinga · Aug 6, 2026, 12:46 PM
Emergent BioSolutions Sees Q3 Sales $110.000M-$130.000M vs $209.000M EstBenzinga · Aug 5, 2026, 8:51 PM
Emergent BioSolutions Lowers FY2026 Sales Guidance from $720.000M-$760.000M to $645.000M-$675.000M vs $733.050M EstBenzinga · Aug 5, 2026, 8:32 PM
Emergent BioSolutions Q2 Adj. EPS $0.60 Beats $0.11 Estimate, Sales $234.300M Beat $177.500M EstimateBenzinga · Aug 5, 2026, 8:23 PM
'White House Adds Pandemic Response Staff as Ebola Cases Rise' - Bloomberg NewsBenzinga · Jul 1, 2026, 4:25 PM
8-K filing — Emergent BioSolutions Inc. (EBS)SEC EDGAR · Jun 29, 2026, 3:14 PM
Emergent BioSolutions Secures $52.7M U.S. Government Contract Modification For ACAM2000 Smallpox And Mpox Vaccine SupplyBenzinga · Jun 29, 2026, 1:20 PM
CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains LowBenzinga · Jun 26, 2026, 5:15 PM